Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 14 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a press release regarding a new clinical trial. This initiative marks a significant step in developing new therapies for Sickle Cell Disease in India. The study aims to assess various health outcomes in patients receiving the treatment compared to a placebo.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 14, 2024, titled "Zydus and ICMR initiate a Phase 2 proof-of-concept trial of Desidustat in patients with Sickle Cell Disease".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases